Premium
Antipsychotic properties of neuroleptic‐like neuropeptides in schizophrenia: A clinical review
Author(s) -
Verhoeven W. M. A.,
Van Ree J. M.
Publication year - 1987
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470020303
Subject(s) - endorphins , ceruletide , cholecystokinin , antipsychotic , schizophrenia (object oriented programming) , neuropeptide , psychology , neuroscience , medicine , endocrinology , pharmacology , psychiatry , receptor
Abstract Recently much interest has been shown in the antipsychotic efficacy of neuroleptic‐like neuropeptides in schizophenia. In this article the clinical effects of the non‐opioid fragments of γ‐endorphin, the so‐called γ‐type endorphins DTγE and DEγE, are reviewed. In addition, preliminary clinical studies of peptides related to cholecystokinin are considered. It is concluded that γ‐type endorphins possess antipsychotic properties in a subgroup of patients who may belong to Type I schizophrenia. With cholecystokinin‐related peptides, in particular ceruletide, antipsychotic effects have been reported which seem to be more or less comparable to those observed with γ‐type endorphins.